These agents are antibodies that induce reactivation of the immune system to target tumor cells by blocking PD-1 or PD-L1 and change the tumor environment by activating tumor-reactive cytotoxic T lymphocytes (CTLs) (8). This evidence concerns the gene CD274 and neoplasm.